CoChat

Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer

Open access
Haines, Eric, Chen, Ting, Kommajosyula, Naveen, Chen, Zhao, Herter-Sprie, Grit S., Cornell, Liam, Wong, Kwok-Kin, Shapiro, Geoffrey I. · 2018 · Oncotarget
Cited by 51

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

// Eric Haines 1 , Ting Chen 1,3 , Naveen Kommajosyula 1 , Zhao Chen 1,4 , Grit S. Herter-Sprie 1,5 , Liam Cornell 1 , Kwok-Kin Wong 1,2,3 and Geoffrey I. Shapiro 1,2 1 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA 2 Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA 3 Perlmutter Cancer Center, New York University, Langone Medical Center, New York, NY, USA 4 Novartis Institutes for BioMedical Research, Cambridge, MA, USA 5 University Hospital of Cologne, Weyertal, Cologne, Germany Correspondence to: Geoffrey I. Shapiro, email: geoffrey_shapiro@dfci.harvard.edu Keywords : CDK4/6 inhibitor; MEK inhibitor; FGFR1; KRAS-mutant non-small cell lung cancer; drug resistance Received: September 03, 2017 Accepted: July 08, 2018 Published: August 03, 2018 Abstract CDK4 is emerging as a target in KRAS -mutant non-small cell lung cancer (NSCLC). We demonstrate that KRAS -mutant NSCLC cell lines are initially sensitive to the CDK4/6 inhibitor palbociclib, but readily acquire resistance associated with increased expression of CDK6, D-type cyclins and cyclin E. Resistant cells also demonstrated increased ERK1/2 activity and sensitivity to MEK and ERK inhibitors. Moreover, MEK inhibition reduced the expression and activity of cell cycle proteins mediating palbociclib resistance. In resistant cells, ERK activated mTOR, driven in part by upstream FGFR1 signaling resulting from the extracellular secretion of FGF ligands. A genetically-engineered mouse model of KRAS -mutant NSCLC initially sensitive to palbociclib similarly developed acquired resistance with increased expression of cell cycle mediators, ERK1/2 and FGFR1. In this model, resistance was delayed with combined palbociclib and MEK inhibitor treatment. These findings implicate an FGFR1–MAP kinase– mTOR pathway resulting in increased expression of D-cyclins and CDK6 that confers palbociclib resistance and indicate that CDK4/6 inhibition acts to promote MAP kinase dependence.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.25803

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

Metadata

Authors
Haines, E., Chen, T., Kommajosyula, N., Chen, Z., Herter-Sprie, G. S., Cornell, L., Wong, K.-K., & Shapiro, G. I.
Venue
Oncotarget
Published
2018-08-03
Volume
9
Issue
60
Pages
31572-31589
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2886814879
Cited by
51
References
22
FWCI
4.73
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.